Reply to an Answer

Yes, Amylin is studying a once-weekly version of Byetta (exenatide). Information from the company about this product is available at their website, at Exenatide Once Weekly. But they don't mention the frequency of nausea with this version. I could find one publication at PubMed about this version: Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, where they state "Mild nausea was the most frequent adverse event" but they don't describe whether it was more or less frequent compared to what's usually expected with the twice-daily version. So, I guess we'll both have to wait for a while longer to find out the answer to your question. Sorry not to be more helpful.